Xolair for chronic hives in NYC

Xolair is FDA-labeled for adults and adolescents age 12 and older with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamine treatment.

The allergy evaluation first confirms CSU rather than acute hives, inducible urticaria, a medication reaction, or another cause of swelling. Coverage, patient-specific delivery, administration, and observation are planned only after eligibility is established.

Xolair can cause anaphylaxis

Xolair has a boxed warning for anaphylaxis. Treatment is initiated in a healthcare setting equipped to manage it, and the clinician sets the observation and administration plan.

What must be confirmed before Xolair for hives

The indication-specific visit protects against treating every recurring rash or swelling as CSU.

A chronic spontaneous pattern

Wheals, angioedema, or both recur for more than six weeks without a consistent external trigger.

Symptoms despite H1 antihistamine treatment

The clinician reviews the antihistamine used, dose, adherence, response, side effects, and other medicines before escalation.

Age and safety eligibility

The Xolair CSU indication begins at age 12. Prior hypersensitivity and anaphylaxis history affect the administration plan.

What to expect from evaluation through follow-up

The order and timing vary by diagnosis, prescribing responsibility, coverage, medication delivery, and the confirmed care site.

1. Confirm CSU

Review symptom duration, photographs, swelling, triggers, lesion behavior, associated symptoms, and findings that suggest another diagnosis.

2. Review antihistamine treatment

Confirm the medication, dose, adherence, benefit, side effects, and whether a clinician-directed optimization plan has been completed.

3. Set a baseline

Record hive and itch activity, angioedema, sleep disruption, daily function, and rescue medicine use so response can be measured.

4. Coordinate access and administration

After the prescription is approved, confirm benefits, patient-specific pharmacy delivery, the eligible clinic, boxed-warning readiness, and observation.

5. Reassess response

Review symptom control and tolerability at defined intervals. The prescriber decides whether to continue, adjust, or reconsider the diagnosis and treatment plan.

Xolair for CSU has a narrow intent

The Xolair chronic-hives pathway is for confirmed CSU, not every rash, acute allergy, or swelling episode.

The FDA-labeled CSU population is age 12 and older and remains symptomatic despite H1 antihistamine treatment.
Xolair is not indicated for other forms of urticaria. Physical triggers, medication reactions, urticarial vasculitis, and hereditary angioedema require different decisions.
Unlike asthma and food-allergy dosing, CSU dosing does not depend on pretreatment total IgE or body weight.
Treatment response is assessed from symptom burden and function, not from repeating total IgE during therapy.

Coverage, outside orders, and specialty-pharmacy delivery

Nao can coordinate these steps when the clinical program and receiving site approve the plan. Coverage, assistance, delivery time, and administration are never guaranteed.

Outside-order review

A valid order is reviewed with the diagnosis, dose, records, responsible prescriber, adverse-event plan, refill responsibility, and follow-up. Acceptance is not automatic.

Benefits and authorization

The care team can review the pharmacy or medical benefit, documentation, prior authorization, appeal path, expected patient cost, and eligible support resources.

Confirmed delivery and appointment

A specialty pharmacy may send patient-specific medication only after Nao provides the accepted clinic and delivery instructions. Administration is scheduled after receipt and safety confirmation.

Safety and escalation

Call 911 for tongue or throat swelling, breathing difficulty, fainting, or a rapidly progressing reaction.
Report any prior Xolair reaction or history of anaphylaxis before treatment.
Keep the clinician-directed antihistamine and emergency plan unless the prescriber changes it.
Do not arrange shipment or arrive for an injection until the receiving clinic confirms the order and appointment.

Review Nao Medical's urgent and emergency care guidance. Call 911 for a life-threatening emergency.

Clinics available for evaluation booking

The specialty route offers evaluation booking across these 11 clinics through the PCP NP visit type. Appointment times vary. An evaluation location is not automatically an administration location. Nao does not promise on-hand medication or same-day injection. The care team confirms the eligible administration site separately for each patient and product.